BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its fourth quarter 2024 financial results on Monday, February 24, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a corporate update. Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of BioCryst's website.

News Market Reaction – BCRX

-1.03%

-1.03% Session move

In the trading session that priced this news, BCRX declined 1.03%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When will BioCryst (BCRX) report Q4 2024 earnings?

BioCryst will report its fourth quarter 2024 financial results on Monday, February 24, 2025.

What time is BioCryst's (BCRX) Q4 2024 earnings call?

BioCryst's Q4 2024 earnings conference call and webcast will be held at 8:30 a.m. ET on February 24, 2025.

How can investors access BioCryst's (BCRX) Q4 2024 earnings call?

Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international), or view the webcast in the investors section of www.biocryst.com.

Where can I find the replay of BioCryst's (BCRX) Q4 2024 earnings call?

A replay of the earnings call will be available in the investors section of BioCryst's website at www.biocryst.com.